Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study
about
Preventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology GuidelineVaccination of adolescents with chronic medical conditions: Special considerations and strategies for enhancing uptakeCurrent global status & impact of human papillomavirus vaccination: Implications for IndiaCervical cancer prevention and treatment research in Africa: a systematic review from a public health perspectiveEurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines.Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule.Human papilloma virus vaccination: impact and recommendations across the world.Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission modelRecent advances in the study of HPV-associated carcinogenesisComparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study.Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.Parents' decision-making about the human papillomavirus vaccine for their daughters: II. Qualitative results.Evaluation of vaccine seroresponse rates and adverse event rates through Bayesian and frequentist methods.HPV Serology Testing Confirms High HPV Immunisation Coverage in England.Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.Overcoming Barriers to Low HPV Vaccine Uptake in the United States: Recommendations from the National Vaccine Advisory Committee: Approved by the National Vaccine Advisory Committee on June 9, 2015Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.Timing of HPV vaccine intervals among United States teens with consideration to the current ACIP schedule and the WHO 2-dose schedule.The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model.An exploration of individual- and population-level impact of the 2-dose HPV vaccination schedule in pre-adolescent girlsTen years of anti-HPV vaccinations: what do we know?Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study.Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs.Extending the Human Papillomavirus Vaccination Programme to Include Males in High-Income Countries: A Systematic Review of the Cost-Effectiveness Studies.Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: a nationwide cohort study.Primary Immunization of Human Papillomavirus Vaccine in the Pediatric Population: What Is the Verdict Now?Cost-effectiveness of human papillomavirus vaccination in Germany.Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9-14 Years: A Randomized Trial.HPV vaccine completion and dose adherence among commercially insured females aged 9 through 26 years in the US.HPV vaccination: The most pragmatic cervical cancer primary prevention strategy.Sex differences among college students in awareness of the human papillomavirus vaccine and vaccine options.Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline.Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development.Cancer screening and prevention in low-resource settings.HPV prophylactic vaccines: lessons learned from 10 years experienceHuman papillomavirus vaccination for men: advancing policy and practice
P2860
Q26749285-597B3BA4-A8CA-492A-A18F-32332C9ED1C3Q26799457-8E28EEE6-1602-4818-B3B4-93C4F181584CQ28079776-856559FF-2CAE-4267-9589-824BAF08B6B6Q28601706-EC313F1D-A268-4516-AF7E-3246DBA0A7FBQ30251868-FF958463-3057-4530-BEAD-696C858BEC66Q30970916-4D2DACC8-5DB4-4250-9AFB-BAF38534CF3CQ30980654-7DD8E3CF-8EF1-4347-8CD8-FB832CC672BAQ33724422-AD231692-6875-4596-9C06-8DA0C047580AQ34704575-BDA0E513-4DBC-4A02-BB7B-8DD475F50095Q34852567-F35E3C1A-AE43-4D72-95C2-35F5BFB41D42Q35606176-191F7A3C-B952-4B3B-BAF4-EF83C7603036Q35886612-0819EB9A-C77B-46B3-A992-3E4EF92DE74FQ35886910-43E815AF-A7AB-48C3-B8DB-6FFC173F87C8Q35887704-E04D2063-00F6-4680-8CA1-37157F49D637Q35887727-4244D08F-77C2-4F90-97F9-3B5785B97EDEQ35950913-3756AD1E-B5FB-4364-A12E-E78AEE552987Q36266671-1619D126-41AA-4674-BD77-8493D49AB9EFQ36472746-C64E78E2-2F37-4EAE-A5B0-477A9C062862Q37118381-A635C9F5-F398-4570-B159-AFEF23CF1DC9Q37135005-0AE035AF-C9BF-4319-988C-1F6190658FFAQ37135272-7C834BE8-2269-470B-86CF-D2FCCDAC028CQ37135276-659A4E7E-9A4D-471A-A848-5A45363D41E2Q37473145-A345BEC0-7B91-4D36-8616-AA761A69564AQ37710523-C755A052-F519-47CB-A4EC-F257EA005E6CQ38255277-CDD06DA6-F7C2-4509-AD50-0501C84FDDBBQ38549643-2D918513-5079-4B7E-88CE-5064C615C9B1Q38733067-2D809DDC-88BE-499D-AD90-F9B929E99F9FQ39306396-B2C92761-030D-4824-97A2-5F92D6349DEAQ40063569-90D62C56-EF2A-42FB-BA04-CD26255FE454Q40168801-0A417EFB-5DA8-444F-8E26-B93DA87F57D9Q40256932-2DB1F138-9FF0-4604-B970-696D41FB46D1Q40470651-AB022C6E-7613-4B26-817E-7AB7C1AD2644Q41692004-07A6EC15-A30E-4653-A93A-6DFF37B79589Q47111040-6EC05A94-EE14-40EF-9B63-12D155CDF711Q47549756-C7B18698-F414-40BD-8835-471AF5C26F12Q53253182-CA11C9B3-1C3E-4221-88FE-9D43D48510B7Q56067928-1E7D16DA-268E-4E7F-BA38-8078D744A8FCQ58452367-F24DC0AE-16DE-497B-B12E-60C903AE0686
P2860
Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Immune response to the HPV-16/ ...... esults from a randomized study
@en
type
label
Immune response to the HPV-16/ ...... esults from a randomized study
@en
prefLabel
Immune response to the HPV-16/ ...... esults from a randomized study
@en
P2093
P2860
P356
P1476
Immune response to the HPV-16/ ...... esults from a randomized study
@en
P2093
Barbara Romanowski
Brian Ramjattan
Florence Thomas
Karin Schulze
Klaus Peters
Linda M Ferguson
Marc Dionne
Murdo Ferguson
Pemmaraju Suryakiran
Peter Hillemanns
P2860
P304
P356
10.4161/HV.28022
P50
P577
2014-02-27T00:00:00Z